A study to determine the relative bioavailability of ACH-0144471 after administration of a tablet or softgel and capsule vs. a liquid filled capsule in healthy volunteers.

Phase 1

Completed

• Conditions: Inflammatory and Immune System - Autoimmune diseases; Complement-mediated diseases

• Registration Number: ACTRN12616001017415
• Lead Sponsor: Achillion Pharmaceuticals Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-08-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

Healthy adult male or female subjects. Females must be of non-child bearing potential. Healthy is defined as having no clinically relevant abnormalities identified by a detailed medical history, physical exam, blood pressure and pulse rate measurements, 12-lead ECG, and clinical laboratory tests.
Healthy volunteers must have a normal weight defined as minimum body weight of 50 kg and a BMI of 18 to 30kg/m2.

Exclusion Criteria

If participants have any of the following criteria, they will be excluded from the study.
- Smokers and have a clinically significant disease or allergy,
- An active infection
- Consume more than 21 alcoholic drinks/week.
- Evidence of drug abuse or have taken prescription medications (systemic and topical) within 14 days prior to dosing.

Study & Design

• Study Type: Interventional
• Study Design: Not specified